Skip to content
Menu

Dianthus Therapeutics, Inc. DNTH

Full chart Compare
Set alert

Price alert · DNTH

All alert types
84.55 USD -0.28 (-0.33%)

Regular-session close

84.20 -0.35 -0.41%

After hours · Nov 20, 7:25 PM ET

82.58 Day range 85.67
35.84 52-week range 117.88
YTD
+105.17%
1 year
+109.33%

5D +1.44 (+1.64%)

8590TueWedThuFriMon89.39
Market cap
4.76B
Revenue (ttm)
2.72M
EPS (ttm)
-4.08
Shares out
56.31M
Forward P/E
-19.83
YTD return
+105.17%
1-year return
+109.33%
50-day average
86.81
200-day average
87.62
Enterprise value
3.94B
Volume
784.84K
Avg volume
848.11K
Open
83.62
Previous close
84.83
Day's range
82.58 – 85.67
52-week range
35.84 – 117.88
Beta
0.26
Analysts
Strong Buy
Price target
139.25 (+64.7%)
Earnings date
Mar 8, 2027

Key statistics

Price / sales
1751.74
Price / book
3.83
Revenue growth
205.60%
Free cash flow
-109.14M
Total cash
837.78M
Total debt
1.21M
Return on equity
-22.61%
Short % of float
18.89%

Fundamental scorecard

3 of 25 checks passed on DNTH’s reported financials

ValueGrowthProfitabilityHealthDividend

3of 25 checks passed

  • Value 0 of 5
  • Growth 0 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
DNTH Revenue — quarterly 1.21M
DNTH Net income — quarterly -46.64M
DNTH EPS — quarterly -0.81

Earnings

DNTH recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Mar 8, 2027Dec 30, 2026-0.96———
Nov 4, 2026Sep 30, 2026-0.94454-0.81+0.13+14.24%
Aug 4, 2026Jun 30, 2026-0.84628-0.90-0.05-6.35%
May 5, 2026Mar 31, 2026-1.17-0.85+0.32+27.35%
Mar 9, 2026Dec 31, 2025-0.98-1.43-0.45-45.92%
Nov 5, 2025Sep 30, 2025-0.86-0.97-0.11-12.79%

Upgrades / downgrades

DNTH analyst upgrades and downgrades
DateFirmActionFromTo
Oct 27, 2026Roth Capitalinit—Buy
Oct 15, 2026HC Wainwright & Co.reitBuyBuy
Sep 11, 2026JP Morganinit—Overweight
Sep 4, 2026Citigroupinit—Buy
Aug 6, 2026Truist SecuritiesmainBuyBuy
Aug 6, 2026HC Wainwright & Co.mainBuyBuy

About Dianthus Therapeutics, Inc.

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on DNTH — it syncs with the Stock Master app.

Insider holders

DNTH insider holders
InsiderRelationLatest transactionDateShares held
CARR EDWARDOfficerSaleMar 11, 20260
GARCIA MARINOChief Executive OfficerSaleAug 6, 202665,292
MCGEORGE ANNEDirectorSaleAug 9, 20260
RANDHAWA SIMRATOfficerSaleAug 31, 20264,000
READ SIMON J.DirectorSaleAug 18, 20260
SAVITZ RYANChief Financial OfficerSaleNov 11, 20260

Institution ownership

DNTH institution ownership
Holder% heldSharesValueReported
FMR, LLC15.19%8,552,759723.14MSep 29, 2026
T. Rowe Price Investment Management, Inc.10.45%5,885,888497.65MSep 29, 2026
Blackrock Inc.7.80%4,389,604371.14MSep 29, 2026
Wellington Management Group, LLP5.34%3,006,167254.17MSep 29, 2026
Fairmount Funds Management LLC4.51%2,537,191214.52MSep 29, 2026
State Street Corporation4.50%2,534,458214.29MSep 29, 2026

Fund ownership

DNTH fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.93%1,649,920139.50MJun 29, 2026
Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund2.83%1,592,149134.62MSep 29, 2026
VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund2.67%1,503,955127.16MJul 30, 2026
SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF2.45%1,380,523116.72MSep 29, 2026
iShares Trust-iShares Russell 2000 ETF2.17%1,224,305103.51MSep 29, 2026
T. Rowe Price Small-Cap Stock Fund, Inc.2.05%1,155,51197.70MJun 29, 2026